Mesothelioma Treatment: Options and Care Planning
Treatment for mesothelioma varies according to where the disease develops, how far it has spread, and a person’s overall health. Cell subtype can also influence which approaches may be suitable. Care often combines more than one treatment, and a specialist multidisciplinary team is generally best placed to guide decisions for an individual patient — this page explains the options and how those decisions are typically approached.
Treatment is individualized.
Location and disease extent influence planning.
Care may combine multiple approaches.
Symptom-directed care matters throughout treatment.
How Mesothelioma Treatment Is Planned
There is no single treatment path for mesothelioma. Instead, a specialist team typically reviews several factors together to build a plan suited to the individual, rather than applying one standard approach to every patient. No single factor determines treatment on its own — the full clinical picture is considered together.
Because this assessment draws on imaging, pathology, and a person’s overall condition, it is usually carried out by a multidisciplinary team rather than a single clinician working alone.
Anatomical Location
Pleural, peritoneal, pericardial, and testicular mesothelioma may be approached differently.
Extent of Disease
How far the disease has spread can affect which options may be appropriate.
Histological Subtype
Epithelioid, sarcomatoid, or biphasic cell patterns may influence planning.
Overall Health
General fitness and organ function help determine which treatments may be tolerated.
Symptoms & Goals
A person’s symptoms and personal treatment goals help shape the plan.
Prior Treatment
Previous surgery or therapy may affect which options remain available.
Important: Only a qualified healthcare team can recommend treatment for an individual patient after reviewing the complete clinical situation.
Mesothelioma Treatment Options
These are the main approaches considered in mesothelioma care. Not every option applies to every patient.
Surgery
May be considered in selected patients to remove or reduce visible disease.
Read more → Systemic TreatmentChemotherapy
Medicines that travel through the bloodstream to reach cancer cells throughout the body.
Read more → Systemic TreatmentImmunotherapy
Helps the immune system recognize and respond to cancer cells in selected situations.
Read more → Local TreatmentRadiation Therapy
Directed at a defined area, sometimes to relieve symptoms or as part of a broader plan.
Read more → Whole-Person CareSupportive & Palliative Care
Addresses symptoms and quality of life alongside disease-directed treatment.
Read more → Emerging ApproachesClinical Trials
Studies of new or modified approaches; participation is voluntary and protocol-specific.
Read more →Systemic Therapy
Systemic medicines travel through the bloodstream and can potentially reach cancer cells throughout the body. Whether a systemic treatment may be considered, and which one, depends on the type and extent of disease, prior treatment, and a person’s overall clinical circumstances.
Chemotherapy
Chemotherapy uses medicines intended to slow or stop the growth of cancer cells. In mesothelioma, combinations of medicines are sometimes used together rather than a single drug alone. A combination of cisplatin and pemetrexed has been a standard systemic option for pleural mesothelioma since the early 2000s, following results from the EMPHACIS clinical trial (U.S. FDA approval, 2004).
Selecting and scheduling chemotherapy requires oncology assessment, and it is not considered mandatory for every patient. Monitoring for side effects is an ongoing part of care throughout treatment.
Immunotherapy
Immunotherapy is designed to help a person’s own immune system recognize and respond to cancer cells, rather than attacking the cancer directly the way chemotherapy does. It may be considered in selected clinical situations rather than for every patient.
In October 2020, the U.S. FDA approved a combination of nivolumab and ipilimumab as a first-line option for unresectable pleural mesothelioma, based on the CheckMate 743 trial. In September 2024, the FDA also approved pembrolizumab combined with pemetrexed and platinum chemotherapy as a first-line option for unresectable, advanced, or metastatic pleural mesothelioma. Suitability and possible side effects for any immunotherapy require specialist assessment, and a response cannot be promised for an individual patient.
When Surgery May Be Considered
Surgery may be considered for some patients, generally depending on the extent of disease, its location, and a person’s overall fitness for a major operation. Surgery experienced specifically with mesothelioma is generally recommended, since these procedures are complex and outcomes can vary between centers.
It is useful to distinguish between surgery intended to remove as much visible disease as possible, and procedures intended mainly to relieve symptoms, such as drainage of fluid buildup. These have different goals and are considered in different circumstances.
Specialist note: Mesothelioma surgery is complex and should be evaluated by a team experienced in treating the relevant anatomical type.
Pleurectomy/Decortication
Described by the American Cancer Society as the most common surgery used to try to remove pleural mesothelioma while aiming to preserve lung function.
Extrapleural Pneumonectomy
A more extensive operation that removes the lung along with surrounding tissue; it carries greater complication risk and is not suitable for every patient.
Cytoreductive Surgery
Used for selected peritoneal mesothelioma to remove as much visible disease as possible from the abdominal cavity.
Symptom-Directed Procedures
Some procedures aim primarily to relieve symptoms, such as draining fluid buildup, rather than removing the tumor itself.
Treatment for Peritoneal Mesothelioma
Care for peritoneal mesothelioma, which develops in the lining of the abdomen, may differ from care for pleural disease. For a subset of patients with peritoneal mesothelioma confined to the abdomen, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) — heated chemotherapy delivered directly into the abdominal cavity during surgery — may be considered.
According to the National Cancer Institute, this combined approach is generally offered to patients with disease confined to the abdomen, a good overall performance status, and a reasonable expectation of achieving substantial surgical removal of visible disease. Not every patient is eligible, and most of the available evidence comes from single-center or retrospective studies rather than large randomized trials, so outcomes can vary between centers and patients. Specialist evaluation at an experienced center is essential to determine whether this approach may be appropriate.
The Role of Radiation Therapy
Radiation therapy directs energy at a defined area of the body to affect cancer cells in that region. In mesothelioma, it may be used as part of a broader treatment plan — for example, alongside surgery — or on its own to help relieve symptoms such as pain in selected situations.
Treatment planning is intended to limit exposure to surrounding healthy tissue as much as possible. Radiation is not appropriate for every anatomical type or stage of mesothelioma, and its role and timing depend on the individual treatment plan developed by the care team.
Note: The role and timing of radiation therapy depend on the individual treatment plan.
Supportive Care During Mesothelioma Treatment
Supportive care, sometimes called palliative care, can be provided alongside disease-directed treatment — it does not mean that treatment has stopped. It focuses on comfort and quality of life and may address pain or discomfort, breathlessness, fluid-related symptoms, nutrition, fatigue, and emotional well-being, as well as practical support for patients and caregivers.
Supportive care can be introduced at any point in the care pathway, from shortly after diagnosis through active treatment and beyond, and is generally provided in addition to — not instead of — other treatment a person may be receiving.
Patient Resources Hub
Practical guidance on care teams and support after diagnosis.
The Mesothelioma Care Team
Mesothelioma care often involves professionals from several specialties working together. Not every patient sees every specialist listed below — involvement depends on individual circumstances.
Medical Oncologist
Oversees systemic treatments such as chemotherapy and immunotherapy.
Thoracic Surgeon
Evaluates and performs surgery involving the chest cavity when appropriate.
Radiation Oncologist
Plans and oversees radiation therapy when it is part of the treatment plan.
Pulmonologist
Supports assessment and management of lung-related symptoms and function.
Radiologist
Interprets imaging studies used throughout diagnosis and monitoring.
Pathologist
Examines tissue samples to confirm diagnosis and identify cell subtype.
Palliative Care Specialist
Focuses on symptom relief and quality of life alongside other treatment.
Peritoneal Disease Specialists
Teams experienced specifically with peritoneal mesothelioma and procedures such as CRS/HIPEC.
Nursing & Support Staff
Provide day-to-day care, education, and coordination throughout treatment.
Clinical Trials and Emerging Approaches
Clinical trials study new or modified treatment approaches, or new combinations of existing treatments. Eligibility depends on the specific trial’s protocol, and participation is always voluntary. As with any treatment decision, the possible risks and benefits of joining a trial should be discussed with the healthcare team — a trial is not guaranteed to help any individual participant.
For general, authoritative information about ongoing studies, the U.S. National Institutes of Health maintains a public clinical-trial registry at clinicaltrials.gov. We do not recommend using unverified commercial trial-matching services to find a study.
How Treatment May Differ by Mesothelioma Type
Mesothelioma is classified by where it develops in the body, and these anatomical types are not equally common or equally studied — which means the evidence base and available treatment approaches differ between them.
Pleural Mesothelioma
The most studied type; surgery, systemic therapy, and radiation are all potentially considered depending on the individual case.
Peritoneal Mesothelioma
Cytoreductive surgery with HIPEC may be considered for selected patients; systemic therapy may also play a role.
Pericardial Mesothelioma
Much less common, with a smaller evidence base; treatment approaches are less standardized.
Testicular Mesothelioma
Very rare, typically identified during surgery for a suspected hydrocele; evidence is limited to case reports and small case series.
Treatment Goals and Prognosis
Treatment goals may include controlling the disease, relieving symptoms, maintaining function or quality of life, and supporting a person’s own priorities for their care — these goals can differ between patients and may change over time.
An individual’s prognosis cannot be predicted from a treatment name alone; it depends on many factors specific to that person. Receiving more aggressive treatment does not guarantee a longer survival for any individual patient. Our prognosis guide explains these factors in more detail.
Preparing to Discuss Treatment
Bringing a few details to your appointment can help make the conversation more productive.
Questions to Ask About Treatment
- What is the goal of the recommended treatment?
- Why is this option being considered for me?
- What alternatives are available?
- What are the important risks and uncertainties?
- How could treatment affect my daily activities?
- How will response or progression be monitored?
- What supportive care is available to me?
- Could a specialist second opinion be useful in my situation?
- Are there relevant clinical trials I might discuss with my team?
- Who should be contacted between appointments if something changes?
Continue Learning
Common Questions About Mesothelioma Treatment
How is mesothelioma treatment chosen?
A specialist team typically weighs the cancer’s location and extent, cell subtype, a person’s overall health, and their personal goals before recommending a plan. No single factor determines treatment on its own.
Can mesothelioma be treated with surgery?
Surgery may be considered for some patients, depending on the disease’s location and extent and a person’s fitness for a major operation. It is not appropriate or recommended for every patient.
What is systemic therapy?
Systemic therapy refers to medicines, such as chemotherapy or immunotherapy, that travel through the bloodstream and can potentially reach cancer cells throughout the body, rather than treating only one area.
How is immunotherapy used in mesothelioma care?
Immunotherapy helps the immune system recognize and respond to cancer cells. It may be considered in selected situations, such as unresectable pleural mesothelioma, but suitability requires specialist assessment and a response cannot be promised.
What is the role of radiation therapy?
Radiation therapy directs energy at a specific area of the body. It may be used alongside other treatments or to help relieve symptoms in selected situations, depending on the individual treatment plan.
What is HIPEC?
HIPEC stands for hyperthermic intraperitoneal chemotherapy — heated chemotherapy delivered directly into the abdominal cavity during surgery. It may be considered alongside cytoreductive surgery for selected patients with peritoneal mesothelioma, though not everyone is eligible.
Can supportive or palliative care be used during active treatment?
Yes. Supportive care can be provided alongside disease-directed treatment at any point in the care pathway; it does not mean treatment has stopped.
Should patients consider a specialist second opinion or clinical trial?
Many patients find it helpful to discuss a second opinion or potential clinical trial with their care team, particularly given how specialized mesothelioma treatment can be. Whether either is appropriate depends on individual circumstances.
Written and editorially reviewed by the MesotheliomaFeed Editorial Team, using publicly available medical research. Original publication: March 28, 2026. This guide was substantially rewritten and fact-checked as part of an editorial update. See our Editorial Policy and Medical Disclaimer.
- National Cancer Institute, Malignant Mesothelioma Treatment (PDQ®)
- American Cancer Society, Treating Malignant Mesothelioma
- U.S. Food and Drug Administration, approval notices for nivolumab/ipilimumab (2020) and pembrolizumab combination therapy (2024) in unresectable pleural mesothelioma
- Peer-reviewed literature on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma
Not Sure What to Do Next?
Review how mesothelioma is diagnosed, understand prognosis, or find a specialist experienced in mesothelioma care.